F. Janku
Molecular Biology · 2011–2021
A researcher in the Science corpus: 7 papers; trusts 6 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 101 citations into it
- Epidemiology — 60 citations into it
- Pulmonary and Respiratory Medicine — 25 citations into it
- Pathology and Forensic Medicine — 17 citations into it
- Pharmacology — 5 citations into it
Whom F. Janku trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Beth Levine
- N. Mizushima
- J. Engelman
- D. Klionsky
- Y. Kabeya
- D. Rubinsztein
- X. Qu
- Robin Mathew
- J. Stockman
- Adrian L. Harris
Who trusts F. Janku overall
Papers from F. Janku's perspective
Ordered by how strongly the researchers F. Janku trusts endorse each paper. Same corpus, a different order for every researcher.
- LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing (EMBO Journal)
- Role for Rab7 in maturation of late autophagic vacuoles (Journal of Cell Science)
- Autophagy in the pathogenesis of disease. (Cell)
- Growth factor regulation of autophagy and cell survival in the absence of apoptosis. (Cell)
- Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor (Proceedings of the National Academy of Sciences of the United States of America)
- TOR signaling in growth and metabolism. (Cell)
- Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes (Autophagy)
- Autophagy: process and function. (Genes & Development)
- Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin (Nature)
- Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. (Journal of Clinical Investigation)
Their papers
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015) — 634 citations
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. (2015) — 375 citations
- Targeting the PI3K pathway in cancer: are we making headway? (2018) — 921 citations
- Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours (2021) — 132 citations
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. (2016) — 1,389 citations
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. (2014) — 767 citations
- Autophagy as a target for anticancer therapy (2011) — 797 citations